These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24937095)

  • 1. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.
    Carnicella S; Drui G; Boulet S; Carcenac C; Favier M; Duran T; Savasta M
    Transl Psychiatry; 2014 Jun; 4(6):e401. PubMed ID: 24937095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson's disease.
    Favier M; Carcenac C; Drui G; Vachez Y; Boulet S; Savasta M; Carnicella S
    Sci Rep; 2017 Jan; 7():41589. PubMed ID: 28134302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramipexole reverses Parkinson's disease-related motivational deficits in rats.
    Favier M; Duran T; Carcenac C; Drui G; Savasta M; Carnicella S
    Mov Disord; 2014 Jun; 29(7):912-20. PubMed ID: 24515412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.
    Scardochio T; Clarke PB
    Psychopharmacology (Berl); 2013 Apr; 226(3):589-600. PubMed ID: 23192317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease.
    Drui G; Carnicella S; Carcenac C; Favier M; Bertrand A; Boulet S; Savasta M
    Mol Psychiatry; 2014 Mar; 19(3):358-67. PubMed ID: 23399912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat.
    Zengin-Toktas Y; Authier N; Denizot H; Chassain C; Hafidi A; Llorca PM; Durif F
    Neuropharmacology; 2013 Jul; 70():74-82. PubMed ID: 23347953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?
    Magnard R; Vachez Y; Carcenac C; Krack P; David O; Savasta M; Boulet S; Carnicella S
    Transl Psychiatry; 2016 Mar; 6(3):e753. PubMed ID: 26954980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?
    Yang P; Perlmutter JS; Benzinger TLS; Morris JC; Xu J
    Ageing Res Rev; 2020 Jan; 57():100994. PubMed ID: 31765822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
    Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats.
    Graham DL; Hoppenot R; Hendryx A; Self DW
    Psychopharmacology (Berl); 2007 Apr; 191(3):719-30. PubMed ID: 16835769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists.
    Khroyan TV; Barrett-Larimore RL; Rowlett JK; Spealman RD
    J Pharmacol Exp Ther; 2000 Aug; 294(2):680-7. PubMed ID: 10900248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is nicotine protective against Parkinson's disease? An experimental analysis.
    García-Montes JR; Boronat-García A; López-Colomé AM; Bargas J; Guerra-Crespo M; Drucker-Colín R
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):897-906. PubMed ID: 23131151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
    Collo G; Zanetti S; Missale C; Spano P
    Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The D2/D3 agonist PD128907 (R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol) inhibits stimulated pyloric relaxation and spontaneous gastric emptying.
    Kashyap P; Micci MA; Pasricha S; Pasricha PJ
    Dig Dis Sci; 2009 Jan; 54(1):57-62. PubMed ID: 18600456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.
    Schneider JS; Marshall CA; Keibel L; Snyder NW; Hill MP; Brotchie JM; Johnston TH; Waterhouse BD; Kortagere S
    Exp Neurol; 2021 Jan; 335():113514. PubMed ID: 33141071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat.
    Lanza K; Chemakin K; Lefkowitz S; Saito C; Chambers N; Bishop C
    Psychopharmacology (Berl); 2020 Jan; 237(1):155-165. PubMed ID: 31435690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice.
    Doherty JM; Masten VL; Powell SB; Ralph RJ; Klamer D; Low MJ; Geyer MA
    Neuropsychopharmacology; 2008 Oct; 33(11):2648-56. PubMed ID: 18075489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.